Close to a decade af­ter Eli Lil­ly killed it, Jef­frey Blue­stone's 'break­through' drug is back and be­ing steered to the FDA

The di­a­betes drug teplizum­ab has tak­en an­oth­er step for­ward in the long, painful­ly slow trek out of the R&D wilder­ness. And the next stop could be the FDA.

Ban­ished to the shelves 9 years ago at Eli Lil­ly, the drug from the lab of UCSF sci­en­tist and Park­er In­sti­tute chief Jef­frey Blue­stone has now won the FDA’s break­through ther­a­py des­ig­na­tion — an elite reg­u­la­to­ry sta­tus that should speed its way in­to the hands of re­view­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER